Clinical Trial Update: Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating safety, tolerability, and long-term immunogenicity of different formulations of a Chikungunya vaccine (V184-005).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya Virus Infection

Drugs mentioned

• V184-005

Snippet

Sponsor: Themis Bioscience GmbH | Conditions: Chikungunya Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2021-10-20